Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?

CancerVolume 129, Issue 7 p. 1129-1130 LETTER TO THE EDITOR Is there a role for combined anti–PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers? Oliver Klein MD, Oliver Klein MD orcid.org/0000-0003-0022-9553 Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, AustraliaSearch for more papers by this authorDamien Kee MD, Damien Kee MD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorAdnan Nagrial MD, Adnan Nagrial MD Blacktown Hospital, Blacktown, New South Wales, Australia University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorBen Markman MD, Ben Markman MD Department of Medical Oncology, Alfred Health, Prahran, Victoria, Australia Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorCraig Underhill MD, Craig Underhill MD Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, New South Wales, AustraliaSearch for more papers by this authorMichael Michael MD, Michael Michael MD Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorAndreas Behren PhD, Andreas Behren PhD Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this authorJodie Palmer PhD, Jodie Palmer PhD Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this authorNiall C. Tebbutt MD, PhD, Niall C. Tebbutt MD, PhD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia University of Melbourne, Melbourne, Victoria, AustraliaSearch for more papers by this authorMatteo S. Carlino MD, PhD, Matteo S. Carlino MD, PhD Blacktown Hospital, Blacktown, New South Wales, Australia University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorJonathan Cebon MD, PhD, Jonathan Cebon MD, PhD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this author Oliver Klein MD, Oliver Klein MD orcid.org/0000-0003-0022-9553 Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, AustraliaSearch for more papers by this authorDamien Kee MD, Damien Kee MD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorAdnan Nagrial MD, Adnan Nagrial MD Blacktown Hospital, Blacktown, New South Wales, Australia University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorBen Markman MD, Ben Markman MD Department of Medical Oncology, Alfred Health, Prahran, Victoria, Australia Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorCraig Underhill MD, Craig Underhill MD Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, New South Wales, AustraliaSearch for more papers by this authorMichael Michael MD, Michael Michael MD Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorAndreas Behren PhD, Andreas Behren PhD Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this authorJodie Palmer PhD, Jodie Palmer PhD Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this authorNiall C. Tebbutt MD, PhD, Niall C. Tebbutt MD, PhD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia University of Melbourne, Melbourne, Victoria, AustraliaSearch for more papers by this authorMatteo S. Carlino MD, PhD, Matteo S. Carlino MD, PhD Blacktown Hospital, Blacktown, New South Wales, Australia University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorJonathan Cebon MD, PhD, Jonathan Cebon MD, PhD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, AustraliaSearch for more papers by this author First published: 24 January 2023 https://doi.org/10.1002/cncr.34660 See correspondence on pages 1131–2, this issue. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume129, Issue71 April 2023Pages 1129-1130 RelatedInformation